Hostname: page-component-745bb68f8f-l4dxg Total loading time: 0 Render date: 2025-01-12T13:04:44.060Z Has data issue: false hasContentIssue false
  • English
  • Français

Fooling Mother Nature: Epigenetics and Novel Treatments for Psychiatric Disorders

Published online by Cambridge University Press:  07 November 2014

Stephen M. Stahl
Get access Rights & Permissions [Opens in a new window]

Extract

Modern formulations of psychiatric disorders hypothesize that mother nature goes awry, causing both genetic and epigenetic disease actions. Genetic disease actions are the consequences of naturally inherited risk genes that have an altered sequence of DNA. This altered DNA sequence theoretically leads to the production of altered gene products in neurons, causing inefficient information processing in various brain circuits, and biasing those circuits towards developing symptoms of a mental illness. Epigenetic disease actions are theorized either to activate risk genes to make an altered gene product or to activate normal genes to make normal gene products but at the wrong time. Epigenetic disease mechanisms theoretically turn normal genes into risk genes by causing normal genes to be expressed in neurons when these genes should be silenced or by causing normal genes to be silenced when they should be expressed.

Type
Trends in Psychopharmacology
Information
CNS Spectrums , Volume 15 , Issue 6 , June 2010 , pp. 358 - 366
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Waddington, CH. The Strategy of the Genes. New York, NY: MacMillan; 1957.Google Scholar
2. Nestler, EJ. Epigenetic mechanisms in psychiatry. Biol Psychiatry. 2009;65:189–90.Google Scholar
3. Stahl, SM. Epigenetics and methylomics in psychiatry. J Clin Psychiatry. 2009;70:1204–1205.Google Scholar
4. Sweatt, JD. Experience-dependent epigenetic modifications in the central nervous system. Biol Psychiatry. 2009;65:191–197.Google Scholar
5. Stahl, SM. Methylated Spirits: Epigenetic Hypotheses of Psychiatric Disorders. CNS Spectr. 2010;15:220–230.Google Scholar
6. Roffman, JL, Gollub, RL, Calhoun, VD. et al. MTHFR 677C to T genotype disrupts prefrontal function in schizophrenia through an interactions witti COMT 158 val to met. Proc Natl Acad Sci. 2008;105:17573–17578.Google Scholar
7. Roffman, JL, Weiss, AP, Decersbach, T, et al. Interactive effects of COMT val108/158Met and MTHFR CB77T on executive function in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:990–995.Google Scholar
8. Stahl, SM. Stahls Essential Psychopharmacology, 3rd edition. New York, NY: Cambridge University Press; 2008.Google Scholar
9. Abdolmaleky, HM, Cheng, KH, Faraone, SV, et al. Hypomethylation of M8-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet. 2006;15:3132–3145.Google Scholar
10. Abdolmaleky, HM, Smith, CL, Zhou, RJ, Thiagalingam, S. Epigenetic alterations of dopaminergic system in major psychiatric disorders. In: Yan, Q, ed. Pharmacogenomics in Drug Discovery and Development. New York, NY: Humana Press, 2008 Google Scholar
11. Roffman, JL, Weiss, AP, Deckersbach, T, et al. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schiz Res. 2007;92:181–188.Google Scholar
12. Roffman, JL, Weiss, AP, Purcell, S, et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry. 2008;63:42–48.Google Scholar
13. Muntjewerff, J-W, Gellekink, H, den Heijer, M, et al. Polymorphisms in catechol-O-methyltransferase and methylenetetrahydrofolate reductase in relation to the risk of schizophrenia. Eur Neuropsychopharmacol. 2008;18:99–106.Google Scholar
14. Muntjewerff, JW, Kahn, RS, Blom, HJ, den Heijer, M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta analysis. Mol Psychiatry. 2006;11:143–149.Google Scholar
15. Lewis, SJ, Zammit, S, Gunnell, D, Smith, GD. A meta analysis of the MTHFR C677T polymorphism and schizophrenia risk. Am J Med Genet B Neuropsychiatr Genet. 2005;135B:2–4.Google Scholar
16. Arinami, T, Yamada, N, Yamakawa-Kobayashi, K, Hamaguchi, H, Toru, M. Methylenete trahydrofolate reductase variant and schizophrenia/depression. Am J Med Genet B Neuropsychiatr Genet. 1997;74:526–528.Google Scholar
17. Abdolmaleky, HM, Smith, CL, Farone, SV, et al. Methylomics in psychiatry: modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet B Neuropsychiatr Genet. 2004;127B:51–59.Google Scholar
18. Monteggia, LM, Kavalali, ET. Rett syndrome and the impact of MeCP2 associated transcriptional mechanisms on neurotransmission. Biol Psychiatry. 2009;65:204–210.Google Scholar
19. Akbarian, S, Huang, H-S. Epigenetic regulation in human brain: focus on histone lysine methylation. Biol Psychiatry. 2009;65:198–203.Google Scholar
20. Veldic, M, Caruncho, JH, Liu, WS, et al. DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons on schizophrenia brains. Proc Nat Acad Sci. 2004;101:348–353.Google Scholar
21. Costa, E. Dong, E, Grayson, DR, Guidotti, A, Ruzicka, W, Veldic. Reviewing the role of DNA (Cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics. 2007;2:29–36.Google Scholar
22. Veldic, M, Kadriu, B, Maloku, E, et al. Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr Res. 2007;91:51–61.Google Scholar
23. Tremolizzo, L, Caraboni, G, Ruzicka, WB, et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci. 2002;99:17095–17100.Google Scholar
24. Abdolmaleky, HM, Cheng, KH, Russo, A, et al. Hypermethylation of the Reelin RELN promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet. 2005;134:60–66.Google Scholar
25. Abdolmaleky, HM, Smith, CL, Zhou, J-R, Thiagalingam, S. Epigenetic modulation of reelin function in schizophrenia and bipolar disorder. In: Fatem, SH, ed. Reelin Glycoprotein: Structure, Biology and Roles in Health and Disease. New York, NY: Springer; 2008.Google Scholar
26. Noh, JS, Sharma, RP, Veldic, M, et al. DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures. Proc Natl Acad Sci. 2005;102:1749–1754.Google Scholar
27. Grayson, DR, Jia, X, Chen, Y, et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci. 2005;102:9341–9346.Google Scholar
28. Mill, J, Tang, T, Kaminsky, Z, et al. Epigenomic profiling reveals DNA methylation changes associated with major psychosis. Am J Hum Genet. 2008;82:696–711.Google Scholar
29. Murphy, BC, O'Reilly, RL, Singh, SM. Site specific cytosine methylation in S-COMT promoter in 31 brain regions with implications for studies involving schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2005;133:37–42.Google Scholar
30. Tochigi, M, Iwamoto, K, Bundo, M, et al. Methylation status of the reelin promoter region in the brain of schizophrenic patients. Biol Psychiatry. 2008;63:530–533.Google Scholar
31. Shimabukuro, M, Sasaki, T, Imamura, A, et al. Global hypomethylation of peripheral leukocyte DNA in male patients with schizophrenia: a potential link between epigenetics and schizophrenia. J Psychiatr Res. 2007;41:1042–1046.Google Scholar
32. Connor, CM, Akbarian, S. DNA methylation changes in schizophrenia and bipolar disorder. Epigenetics. 2008;3:55–58.Google Scholar
33. Stahl, SM. Novel Therapeutics for Depression: L-methylfolate (6(S)-5 methyltetra-hydrofolate (MTHF) as a Trimonoamine Modulator and Antidepressant Augmenting Agent. CNS Spectr. 2007;12:423–428.Google Scholar
34. Freeman, JM, Finkelstein, JM, Mudd, SH. Folate-responsive homocysteinuria and “schizophrenia.” A defect in methylation due to deficient 5, 10-methylenetetrahydrofolate reductase activity. N Eng J Med. 1975;292:491–496.Google Scholar
35. Regland, B, Johansson, BV, Gottfries, CG. Homocysteinemia and schizophrenia as a case of methylation deficiency. J Neural Transm Gen Sect. 1994;98:143–152.Google Scholar
36. Fiso, S, Choi, S-W, Girelli, D, et al. A common mutation in the 5, 10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci. 2002;99:5606–5611.Google Scholar
37. Gilbody, S, Lewis, S, Lightfoot, T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A HuGE Review. Am J Epidemiol. 2007;165:1–13.Google Scholar
38. Goff, DC, Bottiglieri, T, Arning, E, et al. Folate, homocysteine and negative symptoms of schizophrenia. Am J Psychiatry. 2004;161:1705–1708.Google Scholar
39. Godfrey, PSA, Toone, BK, Carney, MWB, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336:392–395.Google Scholar
40. Levine, J, Stahl, Z, Sela, B-A, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry. 2006;60:265–269.Google Scholar
41. Kempisty, B, Skiora, J, Lianeri, M, et al. MTHFD 1958G>A and MTR 2756A>G polymorphisms are associated with bipolar disorder and schizophrenia. Psychiatr Genet. 2007;17:177–181.A+and+MTR+2756A>G+polymorphisms+are+associated+with+bipolar+disorder+and+schizophrenia.+Psychiatr+Genet.+2007;17:177–181.>Google Scholar
42. Zhao, R, Chen, Y, Tan, W, et al. Relationship between dopamine-stimulated phospholipid methylation and the single-carbon folate pathway. J Neurochem. 2001;78:788–796.Google Scholar
43. Sharma, A, Kramer, ML, Wick, PF, et al. D4 dopamine receptor-mediated phospholipid methylation and its implications for mental illnesses such as schizophrenia. Mol Psychiatry. 1999;4:235–246.Google Scholar
44. Nagothu, KK, Rishi, AK, Jaszewski, R, Kocuk, O, Majumdar, AP. Folic acid-mediated inhibition of serum-induced activation of EGFR promoter in colon cancer cells. Am J Physiol Gastrointest Liver Physiol. 2004;287:G541–G546.Google Scholar
45. Cohen, SM, Nichols, A, Wyatt, R, Pollin, W. The administration of methionine to chronic schizophrenia patients: a review of 10 studies. Biol Psychiatry. 1974;8:209–225.Google Scholar
46. Straus, RD, Ritsner, MS, Adler, S, et al. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAMe) augmentation in schizophrenia. Eur Neuropsychopharmacol. 2009;19:14–22.Google Scholar
47. Ingrosso, D, Cimmino, A, Perna, AF, et al. Folate treatment and unbalanced methylation and changes in allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003;361:1693–1699.Google Scholar
48. Lamers, Y, Prinz-Langenohl, R, Bramswig, S, Pietrzik, K. Red blood cell folate concentrations increase more after supplementation with (6S)-5-methyltetrahydrofolate than with folic acid in women of childbearing age. Am J Clin Nutr. 2006;84:156–161.Google Scholar
49. Krauss-Etschmann, S, Shadid, R, Campoy, C, et al. Effects of fish oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial. Am J Clin Nutr. 2007;85:1392–1400.Google Scholar
50. Houghton, LA, Sherwood, KL, Pawlosky, R, Ito, S, O'Connor, DL. (6S)-5-methytetrahydrofolate is at least as effective as folic acid in preventing a decline in blood folate concentrations during lactation. Am J Clin Nutr. 2006;83:842–850.Google Scholar
51. Phiel, CJ, Zhang, F, Huang, EY, Guenther, MG, Lazar, MA, Klein, PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer and teratogen. J Biol Chem. 2001;276:36734–36741.Google Scholar
52. Eyal, S, Yagen, B, Sobol, E, Altschuler, Y, Shmuel, M, Bialer, M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia. 2004;45:737–744.Google Scholar
53. Chuang, D-M, Leng, Y, Marinova, Z, Kim, H-Y, Chiu, C-T. Multiple rales of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009;32:591–601.Google Scholar
54. Guidotti, A, Dong, E, Kundakovic, M, Satta, R, Grayson, DR, Costa, E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacolog Sci. 2008;30:55–60 Google Scholar
55. Perisic, T, Zimmermann, N, Kirmeier, T, et at., Valproate and amitriptyline exert common and divergent influences on global and gene promoter-specific chromatin modifications in rat primary astrocytes. Neuropsychopharmacol. 2010;35:792–805.Google Scholar
56. Dong, E, Nelson, M, Grayson, DR, Costa, E, Guidotti, A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA methylation. Proc Natl Acad Sci. 2008;105:13614–13619.Google Scholar
57. Martinez, MA. RNA Interference and Viruses. New York, NY and Madrid, Spain: Caister Academic Press; 2010.Google Scholar